Cefaclor

• 产品号: DB00833
• CAS号: 53994-73-3
• 分子式: C15H14ClN3O4S
• 分子量: 367.80736

产品别名

• 标题: Cefaclor
• IUPAC标准名: (6R,7R)-7-(2-amino-2-phenylacetamido)-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
• IUPAC传统名: cefaclor
• 商标名: Kefral; Distaclor; Ceclor CD; Alfacet; Alenfral; Alfatil; Ceclor; Panacef; Panoral; Raniclor
• 别名: Cefaclor anhydrous; CCL; Cefaclorum [INN-Latin]; Cephaclor

产品登记号

• CAS号: 53994-73-3

产品性质

• 疏水性(logP): 0.4
• 溶解度: 8.6 mg/mL

产品详细信息

详细说明 (English)

• Drug Groups: approved
• Description: Semisynthetic, broad-spectrum antibiotic derivative of cephalexin. [PubChem]
• Indication: For the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.
• Pharmacology: Cefaclor is a second generation cephalosporin antibiotic with a spectrum resembling first-generation cephalosporins. In vitro tests demonstrate that the bactericidal action of the cephalosporins results from inhibition of cell-wall synthesis. Cefaclor has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: Gram positive aerobes - Staphylococci (including coagulase-positive, coagulase-negative, and penicillinase-producing strains), Streptococcus pneumoniae, and Streptococcus pyogenes (group A ß-hemolytic streptococci). Gram-negative aerobes - Escherichia coli, Haemophilus influenzae (including ß-lactamase-producing ampicillin-resistant strains), Klebsiella sp, and Proteus mirabilis.
• Toxicity: Symptoms of overdose include diarrhea, nausea, stomach upset, and vomiting.
• Affected Organisms: Enteric bacteria and other eubacteria
• Biotransformation: No appreciable biotransformation in liver (approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours).
• Absorption: Well absorbed after oral administration, independent of food intake.
• Half Life: 0.6-0.9 hour
• Protein Binding: 23.5%
• Elimination: Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours.
• References: Hebert AA, Sigman ES, Levy ML: Serum sickness-like reactions from cefaclor in children. J Am Acad Dermatol. 1991 Nov;25(5 Pt 1):805-8. [Pubmed] ; Parra FM, Igea JM, Martin JA, Alonso MD, Lezaun A, Sainz T: Serum sickness-like syndrome associated with cefaclor therapy. Allergy. 1992 Aug;47(4 Pt 2):439-40. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

参考文献

• Hebert AA, Sigman ES, Levy ML: Serum sickness-like reactions from cefaclor in children. J Am Acad Dermatol. 1991 Nov;25(5 Pt 1):805-8. Pubmed
• Parra FM, Igea JM, Martin JA, Alonso MD, Lezaun A, Sainz T: Serum sickness-like syndrome associated with cefaclor therapy. Allergy. 1992 Aug;47(4 Pt 2):439-40. Pubmed